What You Must Know About stock? CymaBay Therapeutics, Inc. (NASDAQ: CBAY)

On 13 May 2020, CymaBay Therapeutics, Inc. (NASDAQ: CBAY) changed 127.17% to recent value of $4.18. The stock transacted 88523808 shares during most recent day however it has an average volume of 1636.57K shares. It spotted trading -68.62% off 52-week high price. On the other end, the stock has been noted 245.45% away from the low price over the last 52-weeks.

CymaBay Therapeutics, Inc. (CBAY) recently reported corporate updates and financial results for the fourth quarter and fiscal year ended December 31, 2019.

Fourth Quarter and Year Ended December 31, 2019 Financial Results

Research and development expenses for the three and twelve months ended December 31, 2019 were $20.9M and $83.8M, respectively. This contrast to R&D expenses of $16.4M and $58.1M for the three and twelve months ended December 31, 2018, respectively. Previous to the decision to halt development of seladelpar in November 2019, research and development expenses in the fourth quarter and twelve months ended 2019 were generally higher than in the corresponding periods in 2018Because of expanding clinical trial activities related to the PBC Phase 3 clinical trial, PSC Phase 2 clinical trial, and other NDA-enabling studies.
General and administrative expenses for the three and twelve months ended December 31, 2019 were $4.5M and $19.2M, respectively.  This contrast to $4.2M and $14.4M for the three and twelve months ended December 31, 2018, respectively. Previous to the decision to halt development of seladelpar, G&A expenses in the fourth quarter and twelve months ended 2019 were higher than in the corresponding periods in 2018 as a result of higher labor costs and other administrative expenses necessary to support expanding development activities.
Net loss for the three and twelve months ended December 31, 2019 was $29.4M, or ($0.43) per diluted share, and $102.8M, or ($1.53) per diluted share, respectively.  This contrast to net loss of $19.4M, or ($0.32) per diluted share, and $72.5M, or ($1.26) per diluted share, in the three and twelve months ended December 31, 2018, respectively. Net loss was higher largely Because of increases in operating expenses, including restructuring charges.

The company has 69.27M of outstanding shares and 64.64M shares were floated in the market. According to the most recent quarter its current ratio was 11.5 that represents company’s ability to meet its current financial obligations. The price moved ahead of 141.06% from the mean of 20 days, 159.60% from mean of 50 days SMA and performed 26.81% from mean of 200 days price. Company’s performance for the week was 129.67%, 141.62% for month and YTD performance remained 113.27%.

 

Leave a Reply

Your email address will not be published. Required fields are marked *